NO974596L - Transplantation of genetically modified cells that have low levels of class I MCH proteins on the cell surface - Google Patents

Transplantation of genetically modified cells that have low levels of class I MCH proteins on the cell surface

Info

Publication number
NO974596L
NO974596L NO974596A NO974596A NO974596L NO 974596 L NO974596 L NO 974596L NO 974596 A NO974596 A NO 974596A NO 974596 A NO974596 A NO 974596A NO 974596 L NO974596 L NO 974596L
Authority
NO
Norway
Prior art keywords
cells
genetically modified
transplantation
class
proteins
Prior art date
Application number
NO974596A
Other languages
Norwegian (no)
Other versions
NO974596D0 (en
Inventor
Gillis R Otten
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of NO974596D0 publication Critical patent/NO974596D0/en
Publication of NO974596L publication Critical patent/NO974596L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Pattedyrceller modifiseres genetisk ved innføringen av gener som koder for virus-avledede MHC ned-regulerende proteiner. Egnede celler for transplantasjon tas fra en donor og transfekteres med en ekspresjonsvektor som koder for ett eller flere virus-avledede MHC ned-regulerende proteiner. De genetisk modifiserte donorcellene ekspanderes ex vivo, om relevant, og transplanteres til en mottagende pattedyrvert. De nedsatte nivåer av klasse l MHC-protein lar de transplanterte cellene overleve under betingelser hvor de genetisk umodifiserte cellene ellers ville være gjenstand for angrep av mottagerens immunsystem. Donorcellene kan modifiseres ytterligere for å målsøke celler eller for å forbedre effektorfunksjonen av dojiorcellene i pattedyrverten.Mammalian cells are genetically modified by the introduction of genes encoding virus-derived MHC down-regulating proteins. Suitable cells for transplantation are taken from a donor and transfected with an expression vector encoding one or more virus-derived MHC down-regulating proteins. The genetically modified donor cells are expanded ex vivo, if applicable, and transplanted to a recipient mammalian host. The reduced levels of class 1 MHC protein allow the transplanted cells to survive under conditions where the genetically unmodified cells would otherwise be subject to attack by the recipient's immune system. The donor cells can be further modified to target cells or to enhance the effector function of the dojior cells in the mammalian host.

NO974596A 1995-04-04 1997-10-03 Transplantation of genetically modified cells that have low levels of class I MCH proteins on the cell surface NO974596L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41610695A 1995-04-04 1995-04-04
PCT/US1996/004648 WO1996031241A1 (en) 1995-04-04 1996-04-03 Transplantation of genetically modified cells having low levels of class i mhc proteins on the cell surface

Publications (2)

Publication Number Publication Date
NO974596D0 NO974596D0 (en) 1997-10-03
NO974596L true NO974596L (en) 1997-12-03

Family

ID=23648556

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974596A NO974596L (en) 1995-04-04 1997-10-03 Transplantation of genetically modified cells that have low levels of class I MCH proteins on the cell surface

Country Status (7)

Country Link
EP (1) EP0820311A4 (en)
JP (1) JPH11503024A (en)
KR (1) KR19980703665A (en)
AU (1) AU712415B2 (en)
CA (1) CA2217297A1 (en)
NO (1) NO974596L (en)
WO (1) WO1996031241A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047914A2 (en) * 1997-04-18 1998-10-29 Roche Diagnostics Gmbh Us6 gene from the human cytomegalovirus (hcmv)
JP2002508976A (en) * 1998-01-14 2002-03-26 ヒューマン ジーン セラピー リサーチ インスティテュート Reduced immunogenic nucleotide expression system for use in gene therapy
EP1020520A1 (en) * 1999-01-15 2000-07-19 Introgene B.V. Prevention of immune related removal of cells from the mammalian body, mutant PML molecules useful therefor
LT2569436T (en) 2010-05-14 2018-03-12 Oregon Health & Science University Recombinant hcmv and rhcmv vectors and uses thereof
US20120020885A1 (en) * 2010-07-26 2012-01-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware MHC-Less cells
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2016011293A1 (en) 2014-07-16 2016-01-21 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
CN108064304A (en) 2015-02-10 2018-05-22 俄勒冈健康与科学大学 Available for the method and composition for generating atypia CD8+ t cell responses
EP3377636A4 (en) 2015-11-20 2019-11-06 Oregon Health & Science University Cmv vectors comprising microrna recognition elements
CN110036112B (en) 2016-10-18 2024-05-10 俄勒冈健康与科学大学 Cytomegalovirus vector for priming T cells restricted by major histocompatibility complex E molecules
BR112019021857A2 (en) * 2017-04-19 2020-06-02 Allogene Therapeutics, Inc. PERFECTED T-CELL METHODS AND COMPOSITIONS
WO2019167973A1 (en) * 2018-03-01 2019-09-06 Kyoto University Cell cycle progression inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2074825C (en) * 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells

Also Published As

Publication number Publication date
WO1996031241A1 (en) 1996-10-10
KR19980703665A (en) 1998-12-05
JPH11503024A (en) 1999-03-23
EP0820311A1 (en) 1998-01-28
EP0820311A4 (en) 2002-09-25
AU712415B2 (en) 1999-11-04
NO974596D0 (en) 1997-10-03
CA2217297A1 (en) 1996-10-10
AU5533896A (en) 1996-10-23

Similar Documents

Publication Publication Date Title
NO974596L (en) Transplantation of genetically modified cells that have low levels of class I MCH proteins on the cell surface
Lake et al. Was the nucleus the first endosymbiont?
Tooze et al. Condensation-sorting events in the rough endoplasmic reticulum of exocrine pancreatic cells.
Popham et al. Muramic lactam in peptidoglycan of Bacillus subtilis spores is required for spore outgrowth but not for spore dehydration or heat resistance
CA2193094A1 (en) The cytoplasmic inhibition of gene expression
GB2136814B (en) Dna vectors
AU3970489A (en) Expression cassette for plants
RU94030817A (en) DNA, PROTEIN, VECTOR, CELL, METHOD OF PRODUCT RECEIVING
RU2007110808A (en) WAYS OF CULTIVATION OF CIRCUS VIRUSES
ES2139591T3 (en) ASIALOGLYC PROTEINS FROM HEPATITIS C VIRUS.
DK0663921T3 (en) Method for Increasing Expression and Reducing Expression Variability of Alien Genes in Plant Cells
KR970701199A (en) Growth Arrest Homeobox Gene
KR930701610A (en) Methods of changing the cell, tissue or host orientation of microorganisms, recombinant microorganisms obtained by this method, and methods of using them in the medical and veterinary arts
EA199900507A1 (en) METHODS OF PREVENTION OF TRANSPLANT TENDING DURING TRANSPLANTATION AND PRODUCING UNIVERSAL CELL-HOST FOR GENETIC THERAPY
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
KR880701285A (en) Vaccine containing F protein of AIDS virus
KR960029343A (en) Extraction of peripheral cytoplasmic proteins from prokaryotic microorganisms in the presence of arginine
KR900702035A (en) Cucumber Mosaic Virus Coat Protein Gene
FI924494A0 (en) OEKAD PRODUKTION AV AVSOENDRARDE PROTEINER I EUKARYOTISKA REKOMBINANTCELLER
KR970010968A (en) Expression System of Erythropoin using Duck Germ Cells
Twardowski et al. Disaggregation of elongation factor 1 by extracts of Artemiasalina
KR880003008A (en) DNA encoding antigenic proteins of the virus virus
Komagata Value of chemosystematic data for predicting anamorph-teleomorph relationships between the genera Rhodotorula and Rhodosporidium
FI951325A (en) Transport of proteins by membrane transfer for pre-matching of xenogeneic transplants and other purposes
RU2001104431A (en) METHOD FOR PRODUCING PROTEINS IN TRANSFORMED YEAST CELLS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application